Dalbavancin Promising in Diabetes-Related Foot Osteomyelitis

Written By :  Jacinthlyn Sylvia
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2023-12-08 03:30 GMT   |   Update On 2023-12-08 03:30 GMT
Advertisement

A recent study finds the potential of the antibiotic dalbavancin in managing diabetes-related foot osteomyelitis, a severe complication affecting patients with diabetes. The findings were published in journal of Infectious Diseases Now.

A total of thirteen patients were included from January 2019 to December 2021, a substantial 85% underwent surgical treatment, underlining the severity of the cases involved. Also, this research encompassed consecutive patients receiving at least one 1500 mg dose of dalbavancin. Dalbavancin was administered as the first-line treatment in 46% of the cases, while 54% received it as a second-line option, required by adverse events linked to prior treatments.

Advertisement

The study reported just one adverse event, highlighting the overall well-tolerated nature of dalbavancin. After a rigorous 6-month follow-up period from the last dalbavancin dose, the findings revealed that 82% of the evaluable patients achieved remission. Remission was defined as the absence of relapsing infection or the need for surgery at the initial or a contiguous site.

These promising results suggest that dalbavancin holds potential as an effective and safe treatment option for diabetes-related foot osteomyelitis, especially when considering its favorable tolerability and notable efficacy in both microbiological and clinical aspects.

Diabetes-related foot osteomyelitis poses a significant health risk to individuals with diabetes, often requiring intricate management strategies. The findings on dalbavancin provide good hope, offering a potential avenue for enhanced treatment outcomes. The efficacy of the antibiotics, coupled with its tolerability profile, positions it as a special candidate in the evolving landscape of diabetes-related complications. Further research and larger-scale trials are anticipated to solidify these preliminary findings, paving the way for more effective and targeted treatments in the realm of diabetic foot complications.

Reference: 

Boucher, A., Pradier, M., Lafondesmurs, B., Thill, P., Patoz, P., Blondiaux, N., Joulie, D., Hennart, B., Robineau, O., & Senneville, E. (2024). Dalbavancin as salvage therapy in difficult-to-treat patients for diabetes-related foot osteomyelitis. In Infectious Diseases Now (Vol. 54, Issue 1, p. 104835). Elsevier BV. https://doi.org/10.1016/j.idnow.2023.104835

Tags:    
Article Source : Infectious Diseases Now

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News